HDAC6 and glioblastoma: These results suggest that, while HDAC6 inhibition exerts antitumor effects via stress induction and viability reduction, the concurrent upregulation of at least C3AR1 and C5AR1 may inadvertently activate complement signaling, potentially counteracting its therapeutic benefits in complement-rich GBM microenvironments.